BAPREXIV Trademark

Trademark Overview

On Tuesday, December 20, 2011, a trademark application was filed for BAPREXIV with the United States Patent and Trademark Office. The USPTO has given the BAPREXIV trademark a serial number of 85499473. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, June 12, 2015. This trademark is owned by Pfizer Inc.. The BAPREXIV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
baprexiv

General Information

Serial Number85499473
Word MarkBAPREXIV
Filing DateTuesday, December 20, 2011
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, June 12, 2015
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 24, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, June 12, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Friday, June 12, 2015ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Friday, June 12, 2015ABANDONMENT - AFTER PUBLICATION
Thursday, June 11, 2015TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, January 13, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 12, 2015EXTENSION 5 GRANTED
Monday, December 15, 2014EXTENSION 5 FILED
Monday, December 15, 2014TEAS EXTENSION RECEIVED
Friday, June 20, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 19, 2014EXTENSION 4 GRANTED
Monday, June 16, 2014EXTENSION 4 FILED
Monday, June 16, 2014TEAS EXTENSION RECEIVED
Thursday, November 7, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 6, 2013EXTENSION 3 GRANTED
Monday, November 4, 2013EXTENSION 3 FILED
Monday, November 4, 2013TEAS EXTENSION RECEIVED
Wednesday, June 19, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2013EXTENSION 2 GRANTED
Monday, May 20, 2013EXTENSION 2 FILED
Tuesday, June 18, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, May 20, 2013TEAS EXTENSION RECEIVED
Friday, December 14, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 12, 2012EXTENSION 1 GRANTED
Wednesday, December 12, 2012EXTENSION 1 FILED
Wednesday, December 12, 2012TEAS EXTENSION RECEIVED
Friday, November 16, 2012TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 19, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 24, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 24, 2012PUBLISHED FOR OPPOSITION
Wednesday, April 4, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 20, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, March 19, 2012ASSIGNED TO LIE
Thursday, March 1, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 23, 2012EXAMINER'S AMENDMENT ENTERED
Thursday, February 23, 2012NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, February 23, 2012EXAMINERS AMENDMENT E-MAILED
Thursday, February 23, 2012EXAMINERS AMENDMENT -WRITTEN
Tuesday, February 21, 2012ASSIGNED TO EXAMINER
Tuesday, January 3, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, December 23, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

baprexiv preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases